IL6 and glioblastoma: The best method to evaluate the hypothesis is a proposed, scientifically rigorous, phase II trial [Table 3] that would use VNS, exploiting the “inflammatory reflex,” to reduce IL-6 levels systemically, and in combination with ICI, create an immune responsive TME in patients with glioblastoma.